key: cord-0808506-ukyxmt1k authors: Porembskaya, O.; Lobastov, K.; Pashovkina, O.; Tsaplin, S.; Schastlivtsev, I.; Zhuravlev, S.; Laberko, L.; Rodoman, G.; Kravchuk, V.; Skvortsov, A.; Saiganov, S. title: Thrombosis of pulmonary vasculature despite anticoagulation and thrombolysis: the findings from seven autopsies date: 2020-10-17 journal: nan DOI: 10.1016/j.tru.2020.100017 sha: 75105df9bb14b4f09b7a8f6acdb97c53c8f3bd9f doc_id: 808506 cord_uid: ukyxmt1k Background Venous thromboembolism (VTE) with the prevalence of pulmonary microcirculatory thrombosis is considered a common complication of novel coronavirus disease (COVID-19) that develops despite anticoagulation. Methods The clinical course of the disease and the autopsy findings of seven deceased patients with verified COVID-19 were analyzed. The chest computed tomography (CT) scan was routinely performed while CT pulmonary angiography and a duplex ultrasound scan (DUS) of the lower limbs were used in cases of suspected VTE. The VTE prophylaxis was administered to all patients with intermediate or therapeutic doses of low-molecular-weight heparin. The histological examination of the lung tissue and other organs was performed with particular attention paid to the pulmonary vasculature. Results Venous thromboembolism, including deep vein thrombosis in one patient and pulmonary artery thrombosis in two patients, was confirmed by imaging tests despite anticoagulation. Systemic thrombolysis was performed in two patients with putative and confirmed pulmonary embolism. An autopsy revealed the signs of acute respiratory distress syndrome in all seven patients. Abnormalities of lung vessels were found in all cases and were represented by dystrophy and necrosis in the endothelium and muscle fibers, and by infiltration by plasmatic cells, neutrophils, and lymphocytes. Multiple clots of variable maturity were observed. All those changes developed despite anticoagulation and were preserved after systemic thrombolysis. Conclusion Inflammatory and prothrombotic changes in the arterial wall in parallel with the lack of lung perfusion may cause diffuse arterial thrombosis in the lungs. This background may be responsible for the low response to systemic anticoagulation and thrombolysis in severe forms of COVID-19. embolism. An autopsy revealed the signs of acute respiratory distress syndrome in all seven patients. Abnormalities of lung vessels were found in all cases and were represented by dystrophy and necrosis in the endothelium and muscle fibers, and by infiltration by plasmatic cells, neutrophils, and lymphocytes. Multiple clots of variable maturity were observed. All those changes developed despite anticoagulation and were preserved after systemic thrombolysis. Inflammatory and prothrombotic changes in the arterial wall in parallel with the lack of lung perfusion may cause diffuse arterial thrombosis in the lungs. This background may be responsible for the low response to systemic anticoagulation and thrombolysis in severe forms of COVID-19. The study was performed without any financial support or funding. Autopsy, COVID-19, deep vein thrombosis, pulmonary embolism, pulmonary artery thrombosis, vascular endothelium Over six months have passed since the start of the worldwide pandemic with the spread of the SARS-CoV-2 virus, but several questions about the pathogenesis and treatment of the disease remain unresolved. A large amount of data on the thrombotic complications of coronavirus disease (COVID-19) has been collected over time. A specific feature of these data is a high prevalence of thrombosis in the vasculature of the pulmonary artery (PA) prevailing over a deep vein thrombosis (DVT) in lower limbs. 1, 2, 3 Such findings were regarded as thromboembolic until detailed histological findings became available. The results of morphological studies showed that thrombus formation in the branches of the pulmonary artery has the underlying inflammatory abnormalities in the vessel wall caused by the cytotoxic effect of both the virus itself and the activated immune cells. 4, 5, 6 Increased D-dimer and other coagulation disturbances that are characteristic of patients with severe COVID-19 allow considering disseminated intravascular coagulation (DIC) as one of the possible causes of thrombosis in the lung vessels and other organs (liver, kidney, pelvic veins). 6, 7, 8, 9 The appearance of venous thromboembolism (VTE) in patients with COVID-19 is associated with unfavorable outcomes. 10 However, there is no single approach to the prevention of VTE in COVID-19, and the guidelines regarding anticoagulant prophylaxis and therapy vary across societies. 11, 12, 13 Thrombotic complications are registered despite the administration of both prophylactic and therapeutic anticoagulation. 2, 3 However, individual studies suggest J o u r n a l P r e -p r o o f reduced mortality with therapeutic anticoagulation in patients on mechanical ventilation, although its rates remain high. 14 Considering the fact that thrombosis of lung vessels can deteriorate the respiratory function and general status of the patient, systemic thrombolysis has been suggested to improve treatment outcomes. However, the published data indicate only temporary benefits in blood oxygenation, with no reported long-term results. 15, 16 This study aimed to assess histological abnormalities in the pulmonary vasculature in the setting of anticoagulant, thrombolytic, and anti-cytokine therapy in deceased patients with COVID-19. We analyzed the clinical course of the disease and the autopsy findings of seven patients with COVID- 19 24 , which has been used as an infection hospital from April 20 to August 10, 2020, though one selective dissection was done. The results were included in this analysis. The patients with increased body temperature and acute respiratory symptoms were admitted to the clinical centers. At admission, all of them underwent a reverse transcriptionpolymerase chain reaction (PCR) test for the detection of SARS-CoV-2 and chest computed tomography (CT). The chest CT was repeated with the patient's deterioration, and CT pulmonary angiography (CTPA) was used in the case of suspicion of pulmonary embolism (PE). A duplex ultrasound scan (DUS) of the lower limbs was used to exclude deep vein thrombosis (DVT) in case of clinical suspicion or identification of the source of PE. In accordance with the national guidelines for the management of COVID-19, patients received the following therapy: specific drugs (hydroxychloroquine in combination with azithromycin, lopinavir/ritonavir), antibiotics (vancomycin, meropenem, ceftriaxone), respiratory support, and symptomatic treatment. The VTE prophylaxis was performed with intermediate doses of low-molecular-weight heparin (LMWH, enoxaparin of 40-60 mg twice daily) that were escalated to therapeutic doses (1 mg/kg twice daily) due to putative or confirmed VTE. Systemic thrombolysis for the alleged or confirmed PE was performed by a recombinant tissue plasminogen activator (tPA) dose of 100 mg intravenously over two hours in two cases. One deceased patient was selected for a non-routine autopsy. He had been admitted to the intensive care unit with a critical disease and received mechanical ventilation three weeks after J o u r n a l P r e -p r o o f the onset of the symptoms when he had not received specific treatment. Despite this, he died 15 hours after admission. The reason for this dissection was to specify histological changes in the absence of pharmacological influence. Dissection was performed using the standard methodology, with the use of protective measures similar to those utilized when caring for patients with COVID-19. The search for potential sources of PE in deep veins of both legs was carried out. Autopsy samples were fixed in formalin. The tissues of the lungs, trachea, bronchi, brain, heart, liver, kidneys, and spleen were examined. The specimens were stained with hematoxylin and eosin. Immunohistological analysis was not performed. The primary objective of the examination was the evaluation of abnormalities and thrombotic processes in the lung vasculature. No informed consent was necessary from the families. All performed procedures and investigations were performed in accordance with the ethical standards of the Institutional Reviewal Boards. The study was conducted without any financial support or funding. The general demographic data of deceased patients are represented in Table 1 . The PCR test confirmed the diagnosis of SARS-CoV-2 infection in five cases. The patients no. 2 and 3 were PCR-negative but had a typical pattern of disease (ground-glass opacities) on the chest CT scan, which allowed confirmation of the diagnosis according to the national guidelines. The first chest CT scan at admission detected multisegmental viral pneumonia in all patients, with the involvement of at least 70-75% of the lung tissue. A multifold increase in ferritin and lactate dehydrogenase (LDH) levels was typical for the patients ( Table 2 ). The Ddimer increased moderately with higher levels (4.2-21.3 mg/L) in critically ill patients. The other changes in hemostasis could be interpreted as a hypocoagulation state ( Table 3) . None of the patients with available parameters of coagulation fulfilled the criteria of DIC by the International Society of Thrombosis and Hemostasis. 17 Thrombocytopenia, with a decrease in platelet count <150x10 9 /L, was observed in only two out of seven patients. Increased prothrombin time and fibrinogen level were not typical for analyzed patients (Table 3) . Structural changes similar to those described above in the other six patients were detected by the histological examination of patient no.7, who had no exposure to any specific treatment before death. Typical patterns of ARDS with severe edema of the lung tissue, casts of fibrin, hyaline membranes, desquamated and proliferating epithelium, surfactant networks, macrophages, and neutrophils in the alveoli were found. Giant alveolocytes with the phenomena of pyroptosis were discovered. The interstitial space was characterized by hyperemia and infiltration with lymphocytes and leukocytes. The walls of the segmental and subsegmental branches of the pulmonary artery appeared to be infiltrated by neutrophils and lymphocytes in parallel with perivascular infiltration. Ongoing thrombosis was registered in the subsegmental branches of the PA despite the hypocoagulative state ( Figure 6 ). No additional clots were discovered in the liver, kidney, and spleen. In contrast with the previously described patients, diapedetic hemorrhages were found in the cerebral cortex, white matter of the hemispheres, and cerebellum. Similar focal hemorrhages were discovered in the lungs, mucous membranes of the stomach, colon, urinary bladder, and the renal calyces. No other histopathological differences except hemorrhagic lesions were observed in the patient no.7 when compared with the previous six ones. Morphological studies testify that angiopathy is the crucial pathogenetic mechanism of thrombotic complications in COVID-19. 4,6 Ultrastructural analysis reveals the destruction of the pulmonary vascular endotheliocytes. 4 Immunohistochemical tests demonstrate the presence of CD45 lymphocytes, CD68 macrophages, CD61 megakaryocytes, CD3-, CD4-, and CD8 T-cells, and CD15 neutrophils in the inflammatory infiltration of the vascular wall and perivascular space. 4, 18 Advanced abnormalities of the lung vasculature are observed with varying frequencies among vessels of different calibers. Clots in the major arteries may be found in a limited number of patients and require differential diagnosis between thrombosis in situ and thromboembolism. By contrast, thrombi in pulmonary microvasculature may be revealed in most of the patients with COVID-19 pneumonia. The cumulative evidence shows that microcirculatory thrombosis could be found in 87% of all deceased patients, while thrombosis of large PA branches was found in only 13% of autopsies (Table 5) if DIC could be prevented, there is another potential underlying mechanism of COVID-19 associated thrombosis. It has been shown that impaired fibrinolysis related to the increased level of plasminogen activator inhibitor-1 (PAI-1) and thrombin activatable fibrinolysis inhibitor (TAFI) may lead to the thrombotic complications in severe COVID-19. 23 The hypofibrinolysis can develop either as a systemic or local effect due to PAI-1 release from endothelial cells. 23 However, no reliable data support the efficacy of prophylactic or therapeutic anticoagulation in preventing the pulmonary vasculature thrombosis in COVID-19. Venous thromboembolism with a predominantly thrombotic lesion of PA and arterial thrombotic events were detected despite anticoagulation in previous reports. 2, 3, 24 The postmortem examination of patients who received anticoagulants identified disseminated clots in the lung vasculature. 6, 8, 9 J o u r n a l P r e -p r o o f We can assume that the lack of anticoagulant activity in the pulmonary vasculature may be related to the decreased perfusion. The reason for this is a blood flow shunt in the dead spaces, vascular constriction, and blood stasis caused by lung tissue destruction and pulmonary edema. 19, 20 At the same time, microcirculation in other organs is preserved, and anticoagulant therapy with maintained blood flow prevents thrombus formation at the background of angiopathy. According to the previously published data, microcirculatory thrombosis outside the lung is rarely observed (Table 5 ). However, the ongoing destructive processes in the arterial wall can lead to necrotic injury, resulting in the failure of organ function. 9, 19 Impaired levels of AST, ALT, creatinine, and GRF, observed in some patients, can be considered as the signs of such dysfunction. Lower doses and longer duration may be preferred. Coronavirus disease caused by the SARS-CoV-2 virus is associated with a high incidence of thrombotic complications. The most important among these is thrombosis of the lung vasculature. Clots in the small PA branches may aggravate the severity of the disease, affect Lille ICU Haemostasis COVID-19 group. Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 Endothelial cell infection and endotheliitis in COVID-19 Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective Clinicopathologic Case Series Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19 Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19 COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis Catheter-directed thrombolysis in COVID-19 pneumonia with acute PE: Thinking beyond the guidelines Guidelines for the diagnosis and management of disseminated intravascular coagulation Pulmonary postmortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases Coagulopathy of Coronavirus Disease COVID19 coagulopathy in Caucasian patients Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis Humanitas COVID-19 Task Force Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive All authors declare no competing interests.